152 related articles for article (PubMed ID: 8854651)
1. Effect of deamino-8-D-arginine desmopressin in uremic bleeding.
Hong SY; Yang DH
Korean J Intern Med; 1996 Jun; 11(2):145-50. PubMed ID: 8854651
[TBL] [Abstract][Full Text] [Related]
2. Blood fibrinolysis and the response to desmopressin in glomerulonephritis.
Brommer EJ; Van den Wall Bake AW; Dooijewaard G; van Loon BJ; Emeis JJ; Weening JJ
Thromb Haemost; 1994 Jan; 71(1):19-25. PubMed ID: 8165642
[TBL] [Abstract][Full Text] [Related]
3. Hemostatic and fibrinolytic response to desmopressin in uremic patients.
Chen KS; Huang CC; Leu ML; Deng P; Lo SK
Blood Purif; 1997; 15(2):84-91. PubMed ID: 9087815
[TBL] [Abstract][Full Text] [Related]
4. Fibrinolytic and haemostatic responses to desamino-D-arginine vasopressin (DDAVP) administered by intravenous and subcutaneous routes in healthy subjects.
MacGregor IR; Roberts EM; Prowse CV; Broomhead AF; Ozolins M; Litka P
Thromb Haemost; 1988 Feb; 59(1):34-9. PubMed ID: 3129807
[TBL] [Abstract][Full Text] [Related]
5. Thrombosis following desmopressin for uremic bleeding.
Byrnes JJ; Larcada A; Moake JL
Am J Hematol; 1988 May; 28(1):63-5. PubMed ID: 3259400
[TBL] [Abstract][Full Text] [Related]
6. Infusion of DDAVP does not improve primary hemostasis in patients with cirrhosis.
Arshad F; Stoof SC; Leebeek FW; Ruitenbeek K; Adelmeijer J; Blokzijl H; van den Berg AP; Porte RJ; Kruip MJ; Lisman T
Liver Int; 2015 Jul; 35(7):1809-15. PubMed ID: 25522671
[TBL] [Abstract][Full Text] [Related]
7. Evidence of a local mechanism for desmopressin-induced tissue-type plasminogen activator release in human forearm.
Wall U; Jern S; Tengborn L; Jern C
Blood; 1998 Jan; 91(2):529-37. PubMed ID: 9427706
[TBL] [Abstract][Full Text] [Related]
8. Repeated infusions of DDAVP induce low response of FVIII and vWF but not of plasminogen activators.
Vicente V; Estellés A; Laso J; Moraleda JM; Rivera J; Aznar J
Thromb Res; 1993 Apr; 70(2):117-22. PubMed ID: 8322282
[TBL] [Abstract][Full Text] [Related]
9. Biologic response to subcutaneous and intranasal therapy with desmopressin in a large Amish kindred with Type 2M von Willebrand disease.
Sharthkumar A; Greist A; Di Paola J; Winay J; Roberson C; Heiman M; Herbert S; Parameswaran R; Shapiro A
Haemophilia; 2008 May; 14(3):539-48. PubMed ID: 18312368
[TBL] [Abstract][Full Text] [Related]
10. Experience of desmopressin (DDAVP) administration in patients with congenital and acquired bleeding disorders.
Tsay W; Shen MC
J Formos Med Assoc; 1992 Oct; 91(10):962-9. PubMed ID: 1362675
[TBL] [Abstract][Full Text] [Related]
11. Desmopressin (DDAVP) for treatment of disorders of hemostasis.
Mannucci PM
Prog Hemost Thromb; 1986; 8():19-45. PubMed ID: 3104987
[TBL] [Abstract][Full Text] [Related]
12. Impaired fibrinolytic response to DDAVP in patients with von Willebrand's disease.
Sultan Y; Loyer F; Venot A
Nouv Rev Fr Hematol (1978); 1992; 34(1):55-60. PubMed ID: 1523100
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of desmopressin effect on primary haemostasis in pediatric patients with aspirin-like defect as hereditary thrombocytopathy.
Tauer JT; Gneuss A; Lohse JE; Jürgens T; Knöfler R
Klin Padiatr; 2011 May; 223(3):169-72. PubMed ID: 21509710
[TBL] [Abstract][Full Text] [Related]
14. Uremic plasma after infusion of desmopressin (DDAVP) improves the interaction of normal platelets with vessel subendothelium.
Escolar G; Cases A; Monteagudo J; Garrido M; Lopez J; Ordinas A; Revert L; Castillo R
J Lab Clin Med; 1989 Jul; 114(1):36-42. PubMed ID: 2738447
[TBL] [Abstract][Full Text] [Related]
15. Fibrinolytic capacity following stimulation with desmopressin acetate in patients with diabetes mellitus.
Grant MB; Fitzgerald C; Guay C; Lottenberg R
Metabolism; 1989 Sep; 38(9):901-7. PubMed ID: 2505017
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and haematological effects of desmopressin.
Köhler M; Harris A
Eur J Clin Pharmacol; 1988; 35(3):281-5. PubMed ID: 3141199
[TBL] [Abstract][Full Text] [Related]
17. 1-Deamino-8-D-arginine vasopressin lowers protein C activity in uremics.
Aunsholt NA; Schmidt EB; Stoffersen E
Nephron; 1989; 53(1):6-8. PubMed ID: 2506477
[TBL] [Abstract][Full Text] [Related]
18. Secretory response of the vessel wall to DDAVP and venous occlusion in von Willebrand's disease.
Bykowska K; Letowska M; Sabliński J; Binder BR; Kopeć M; Lopaciuk S
Acta Haematol Pol; 1994; 25(3):261-8. PubMed ID: 7992599
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of desmopressin effects on haemostasis in children with congenital bleeding disorders.
Hanebutt FL; Rolf N; Loesel A; Kuhlisch E; Siegert G; Knoefler R
Haemophilia; 2008 May; 14(3):524-30. PubMed ID: 18284449
[TBL] [Abstract][Full Text] [Related]
20. Increased amounts of von Willebrand factor are bound to microparticles after infusion of desmopressin.
Trummer A; Haarmeijer B; Werwitzke S; Wermes C; Ganser A; Budde U; Tiede A
Haemophilia; 2013 Mar; 19(2):236-41. PubMed ID: 23051555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
